Italy · Delayed Price · Currency is EUR EL.En. Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 3.3% revenue growth to EUR 145.6 million, driven by strong medical sector performance and improved margins, while industrial sales declined but segment profitability rose. Guidance for 2026 is confirmed, with both segments expected to contribute to growth.
Fiscal Year 2025
-
FY2025 saw 4.4% revenue growth and strong medical sector performance, but net profit declined due to FX losses, higher provisions, and one-time items. Guidance for 2026 is cautious, targeting 5% growth amid geopolitical and supply chain risks.
-
Strong Q3 driven by medical sector growth and high-margin products, with consolidated revenue up 3.9% and gross margin improving. Industrial segment faced delays and competition, but cash position strengthened by asset sales. Confident in meeting 2024 guidance.
-
Revenue grew 5.1% to €285M in H1 2025, led by medical sector gains, but EBIT and net income declined due to weaker industrial performance, FX losses, and absence of prior year one-offs. Strong order backlog supports 2025 guidance, with risks from tariffs and market softness.
-
Revenue grew 8.8% year-over-year to EUR 140.9 million, with both medical and industrial sectors contributing. EBIT and margins improved, and 2025 guidance was raised, expecting to beat 2024 revenue and EBIT. U.S. tariffs and global uncertainties remain key risks.
-
A majority stake in Penta Laser Zhejiang was sold to YOFC for EUR 30.5 million, with Ot-las retaining a minority stake and Italian operations remaining independent. 2025 guidance targets revenue growth, especially in industrials, and stable EBIT, with margin pressure expected.
Fiscal Year 2024
-
2024 saw medical segment growth and industrial decline, with strong margins and net income up 7%. Guidance for 2025 is cautious due to global uncertainties, legal risks, and expected revenue loss from key clients, but financial solidity and internal investment remain priorities.
-
Q3 2024 saw a recovery in profitability, with EBIT nearly matching 2023 levels despite a 5.4% revenue decline year-over-year. The medical sector grew, offsetting industrial weakness, and the planned sale of the laser cutting business will shift future focus and reporting.
-
A preliminary agreement was signed to sell majority stakes in the laser cutting division to YOFC for EUR 55.3 million, with closing expected in early 2025. The deal will significantly improve the net financial position and allow a strategic focus on the medical business, with future M&A possible but not yet planned.
-
H1 2024 saw revenues fall 9.5% year-over-year, mainly due to industrial sector weakness, but net income rose to EUR 27.3 million, aided by a one-time gain. Medical sector resilience and a favorable sales mix support guidance for higher EBIT in 2024.